GLPwatch
Soliqua for Obesity
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSoliqua (lixisenatide) is not FDA-approved for obesity, and any use for this condition is off-label or investigational. Research includes studies on weight loss and side effects in obesity and type 2 diabetes, but these do not establish efficacy for obesity treatment.
AI summary of the sources below.
| Drug | Soliqua (lixisenatide) |
|---|---|
| Condition | Obesity |
| Approval status | Investigational / off-label |
| Research papers | 12 |
Soliqua is not FDA-approved for obesity; the research below reflects investigational or off-label study only.
Research on lixisenatide for obesity (12)
- Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
- Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
- Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.
- GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.
- Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
- Kinetic control of Phytic acid/Lixisenatide/Fe (III) ternary nanoparticles assembly process for sustained peptide release.
- [Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].
- Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
- The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.
- Poly(l-threonine-<i>co</i>-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.
- Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.